CLDI on NYSE
Calidi Biotherapeutics, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Entera Bio Ltd., Inmune Bio, Inc. or BioCardia, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2022
Where the money goes
Where each dollar of revenue went, fiscal 2022
- Research and development31¢$7.3M
- Selling, general and admin69¢$15.9M
- Income tax0¢$11.0K
Out of $45.0K in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | -$9.7M | -$8.9M |
| General and administrative | -$10.5M | -$12.9M |
| Total operating expense | -$20.2M | -$21.8M |
| Loss from operations | -$20.2M | -$21.8M |
| Change in fair value of other liabilities and derivatives | $1.0K | $285.0K |
| Change in fair value of other liabilities and derivatives related party | $1.0K | $39.0K |
| Grant income | $50.0K | $181.0K |
| Gain on sale of investment in Nova Cell | $244.0K | |
| Other income, net | $103.0K | $9.0K |
| Total other income (expenses), net | $192.0K | -$419.0K |
| LOSS BEFORE INCOME TAXES | -$20.0M | -$22.2M |
| Income tax provision | -$15.0K | -$14.0K |
| NET LOSS | -$20.1M | -$22.2M |
| Net loss attributable to noncontrolling interest | -$157.0K | -$66.0K |
| NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST | -$19.9M | -$22.1M |
| Deemed dividend on warrants | -$5.7M | -$1.7M |
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | -$25.6M | -$23.8M |
| Net loss per share, basic | -$5.95 | -$35.70 |
| Net loss per share, diluted | -$5.95 | -$35.70 |
| Weighted average common shares outstanding, basic | 4.3K shares | 667 shares |
| Weighted average common shares outstanding, diluted | 4.3K shares | 667 shares |
Every line of the balance sheet in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2025-07-31 | 2024-12-31 |
|---|---|---|---|
| Cash | $5.6M | $9.6M | |
| Prepaid expenses and other current assets | $656.0K | $636.0K | |
| Total current assets | $6.3M | $10.2M | |
| Machinery and equipment, net | $781.0K | $869.0K | |
| Operating lease right-of-use assets, net | $1.7M | $2.9M | |
| Other noncurrent assets | $138.0K | $152.0K | |
| TOTAL ASSETS | $8.9M | $14.2M | |
| Finance lease liability, current | $111.0K | $66.0K | |
| Operating lease right-of-use liability, current | $1.4M | $1.2M | |
| Total current liabilities | $3.9M | $9.5M | |
| Operating lease right-of-use liability, noncurrent | $277.0K | $1.8M | |
| Finance lease liability, noncurrent | $171.0K | $145.0K | |
| Promissory note | $600.0K | $600.0K | |
| Warrant liability | $107.0K | $119.0K | |
| Related party warrant liability | $8.0K | $9.0K | |
| TOTAL LIABILITIES | $5.1M | $12.2M | |
| Common stock, $0.0001 par value, 330,000 shares authorized; 7,217 and 1,730 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $1.0K | ||
| Additional paid-in capital | $145.4M | $123.3M | |
| Accumulated other comprehensive loss, net of tax | -$13.0K | -$28.0K | |
| Accumulated deficit | -$141.6M | -$121.7M | |
| Total stockholders equity | $3.8M | $1.5M | |
| Noncontrolling interest | $434.0K | ||
| Total equity | $3.8M | $2.0M | |
| TOTAL LIABILITIES AND TOTAL EQUITY | $8.9M | $14.2M | |
| Common stock, par value | $0.00 | $0.00 | $0.00 |
| Common stock, shares authorized | 330.0M shares | 330.0M shares | |
| Common stock, share issued | 7.2M shares | 1.7M shares | |
| Common stock, shares outstanding | 7.2M shares | 1.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$20.1M | -$22.2M |
| Depreciation and amortization expense | $1.7M | $1.5M |
| Amortization of debt discount and financing costs | $45.0K | |
| Stock-based compensation | $2.1M | $3.0M |
| Change in fair value of other liabilities and derivatives | -$2.0K | -$324.0K |
| Gain on sale of investment in Nova Cell | -$244.0K | |
| Prepaid expenses and other current assets | -$42.0K | $1.8M |
| Accounts payable | -$1.3M | -$628.0K |
| Accrued expenses and other current liabilities | -$2.0M | -$1.9M |
| Operating lease right of use liability | -$1.4M | -$1.0M |
| Net cash used in operating activities | -$21.3M | -$19.7M |
| Purchases of machinery and equipment | -$120.0K | -$16.0K |
| Cash disposed in sale of investment in Nova Cell | -$50.0K | |
| Net cash used in investing activities | -$170.0K | -$16.0K |
| Proceeds from public offerings | $9.9M | $13.9M |
| Proceeds from warrant inducement financing | $4.1M | $2.1M |
| Proceeds from registered direct offering | $3.5M | |
| Proceeds from at the market offering | $3.3M | $3.1M |
| Proceeds from exercise of pre-funded warrants | $5.0K | $2.0K |
| Repayment of financing lease obligations | -$90.0K | -$82.0K |
| Repayment of principal on term notes payable | -$200.0K | -$300.0K |
| Repayment of principal on related party bridge loan payable | -$200.0K | |
| Payment of financing costs | -$846.0K | -$1.6M |
| Repayment of principal on related party term notes payable | -$2.0M | |
| Proceeds from issuance of noncontrolling interest in Nova Cell | $2.0M | |
| Proceeds from issuance of convertible notes payable | $3.0M | |
| Related party proceeds from issuance of loan payable | $200.0K | |
| Proceeds from issuance of promissory note | $600.0K | |
| Proceeds from issuance of common stock and warrants per subscription agreement | $1.0M | |
| Proceeds from exercise of common stock warrants | $4.8M | |
| Repayment of convertible note payable | -$1.5M | |
| Payment of debt issuance costs | -$9.0K | |
| Net cash provided by financing activities | $17.5M | $27.4M |
| Effect of exchange rate changes on cash | $14.0K | -$13.0K |
| NET (DECREASE) INCREASE IN CASH AND RESTRICTED CASH | -$4.0M | $7.6M |
| Cash paid for interest | $1.3M | $140.0K |
| Cash paid for income taxes | $17.0K | $14.0K |
| Deemed dividend on warrants | $5.7M | $1.7M |
| Machinery and equipment acquired through financing leases | $152.0K | |
| Financing fees included in accounts payable and accrued liabilities | $27.0K | -$91.0K |
| Issuance of common stock per conversion of convertible note | $3.1M | |
| Issuance of convertible note for legal settlement | $1.5M | |
| Issuance of common stock in lieu of cash for services | $289.0K | |
| Related party issuance of common stock in lieu of cash for services | $80.0K | |
| Issuance of common stock and warrants for legal settlement | $308.0K | |
| Debt discount on Convertible Notes | $109.0K | |
| Issuance of common stock in lieu of cash for SEPA commitment fee | $81.0K | |
| Issuance of restricted stock units for liability settlement | $133.0K |
Former names
- First Light Acquisition Group, Inc.May 17, 2021 to Sep 19, 20232
Recent filings
- Sep 25, 20268-K
- Sep 22, 20268-K
- Sep 17, 2026424B5
- Aug 19, 20264
- Aug 19, 20264
- Aug 19, 20264
- Aug 19, 20264
- Aug 19, 20264
- Aug 19, 20264
- Aug 19, 20264
- Aug 19, 20264
- Aug 14, 2026SCHEDULE 13G/A
- Aug 13, 20268-K
- Aug 13, 202610-Q
- Jul 31, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9